Alira Health and AiNA Launch the AXIS Registry to Transform Autoimmune Neurology Research

In April 2026, Alira Health and the Autoimmune Neurology Alliance (AiNA) launched the AXIS Registry to revolutionize care for autoimmune neurological conditions, particularly myasthenia gravis (MG). By bringing together patients and clinicians, this shared platform captures real-world data to optimize treatments, accelerate critical research, and empower patients to actively engage in their healthcare journeys.

The AXIS Registry: Mapping the Future of Autoimmune Health

The AXIS Registry is a 10-year digital platform designed to advance research into rare autoimmune neurological conditions like myasthenia gravis. It accomplishes this by tracking longitudinal real-world data. The registry empowers patients and providers by integrating patient-reported outcomes with clinical records, allowing for a better understanding of disease variations and aligning treatments with actual patient experiences.

For researchers and life sciences organizations, the registry provides scalable data that can accelerate drug development, optimize clinical trial recruitment, and enhance study designs. This continuous feedback loop fosters collaboration across the healthcare community, enabling it to navigate the rapidly evolving landscape of targeted therapies in autoimmune neurology.

According to Precedence Research, the Autoimmune Neurological Disorders Market size was calculated at USD 8.50 billion in 2025 and is predicted to increase from USD 9.17 billion in 2026 to approximately USD 17.79 billion by 2035, expanding at a CAGR of 7.90% from 2026 to 2035. The market growth is attributed to the rising investments in targeted therapies, particularly monoclonal antibodies and RNA-based therapeutics, aimed at halting immune system attacks on the central and peripheral nervous systems.

Why Real-World Evidence is the New Frontier for Autoimmune Drugs

The alliance emphasizes the necessity for rigorous evidence supporting the efficacy and safety of novel biologics before they receive clinical approval. This requirement indicates a tightening of regulatory standards for targeted immunotherapies in the market for autoimmune neurological disorders. In this context, positive data from the AXIS Registry becomes strategically important for biopharmaceutical innovators. If the registry can successfully demonstrate consistent real-world outcomes, new treatments could become the preferred standard of care, potentially strengthening pharmaceutical companies competitive positions in the evolving landscape of autoimmune treatment.

A recent report by Precedence Research highlights that the Autoimmune Neurological Disorders Market is benefiting from rising investments in targeted biologic therapies and RNA-based technologies to address complex conditions like multiple sclerosis and myasthenia gravis.